Study type: Human research · Status: Verified against declared source

Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases

The International Journal of Neuropsychopharmacology · 2016

Study scale: The present investigation was conducted in 158 patients with mild-to-moderate probable AD included in a RCT (clinicaltrials.gov number NCT00911807) that completed the study and were suitable for the per-protocol analysis.

Abstract only: Open source record

Product or molecular entity relationships

Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

The present investigation was conducted in 158 patients with mild-to-moderate probable AD included in a RCT (clinicaltrials.gov number NCT00911807) that completed the study and were suitable for the per-protocol analysis.

Key findings

Low circulating brain derived neurotrophic factor may promote cognitive deterioration, but the effects of neurotrophic and combination drug therapies on serum brain derived neurotrophic factor were not previously investigated in Alzheimer’s disease.

Limitations and uncertainty

Changes in BDNF levels at week 16 and week 28 correlated negatively with baseline BDNF values in the total study population (r=-0.444 and r=-0.488, respectively; P<.001), and these correlations were significant in each of the treatment groups.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.